Clinical Trials
6 trialsNCT05494697 2025-10-14
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
AIM ImmunoTech Inc.
Phase 2 Suspended
NCT05927142 2025-02-25
DURIPANC
Erasmus Medical Center
Phase 1/2 Recruiting
NCT01545141 2023-10-27
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT03403634 2022-03-02
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Roswell Park Cancer Institute
Phase 2 Completed
NCT04119830 2022-02-08
Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT02615574 2017-09-26
A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer
University of Pittsburgh
Phase 2 Withdrawn